Melbourne, Australia & Palo Alto, CA – December 10, 2025 – Telix Pharmaceuticals Limited and Varian, a Siemens Healthineers company, have announced a strategic clinical collaboration to integrate theranostic radiopharmaceuticals with external beam radiation therapy (EBRT), aiming to advance precision oncology through enhanced patient selection, targeted treatment planning, and real-time response assessment. The partnership brings together Telix’s expanding portfolio of molecular imaging and therapeutic radiopharmaceuticals with Varian’s global leadership in EBRT technologies, beginning with the use of PSMA-PET imaging for prostate cancer radiotherapy patients.
Science Significance
This collaboration is scientifically significant because it unites molecularly targeted imaging with adaptive radiation therapy, creating a powerful framework for matching patients to the most effective radiation dose and technique. Telix’s products, including Gozellix® and Illuccix®, provide high-sensitivity PSMA-PET imaging that can map biologically active tumor sites and guide Varian’s EBRT systems, including the Ethos adaptive radiotherapy platform, toward more precise delivery of therapeutic radiation. By combining radiopharmaceutical diagnostics with treatment-planning algorithms and advanced radiation workflows, the partnership aims to accelerate new scientific insights into tumor heterogeneity, radiation responsiveness, and the refinement of personalized prostate cancer therapy.
Regulatory Significance
The collaboration highlights important regulatory considerations in the evolving theranostics + EBRT landscape. Telix’s approved radiopharmaceuticals already operate under stringent regulatory frameworks related to radiation safety, adverse event reporting, and diagnostic accuracy. As the companies pursue additional clinical trials under cooperative and investigator-initiated models, regulators will gain new datasets that define the convergence of PET imaging biomarkers with radiation-treatment outcomes. Programs involving pipeline agents such as TLX250-CDx (Zircaix®) and TLX101-CDx (Pixclara®) could advance into broader regulatory engagement, potentially shaping new guidelines for evidence standards in combination regimens involving EBRT and radiopharmaceutical theranostics.
Business Significance
Advertisement
For both companies, the collaboration represents a major business opportunity in the rapidly rising field of precision radiation oncology. Telix gains expanded clinical visibility for its approved and pipeline radiopharmaceuticals, reinforcing its market leadership in PSMA-targeted imaging and opening pathways for future therapeutic radiopharmaceuticals to enter EBRT-integrated care protocols. Varian strengthens its position by incorporating biologically rich imaging data into its radiation-therapy ecosystem, offering oncologists a more complete decision-support framework. With both company-sponsored and investigator-led trials enabled under the agreement, this partnership is positioned to yield commercial synergies, broader clinical adoption, and long-term value creation in a high-growth oncology segment.
Patients’ Significance
For patients, particularly those with prostate cancer, the synergy of PSMA-PET imaging and precision radiotherapy could deliver significantly more tailored, effective, and less toxic treatment pathways. Enhanced visualization of cancer sites allows oncologists to refine treatment fields, reduce radiation exposure to surrounding tissues, and closely monitor therapeutic response. Integrating Telix’s targeted imaging with Varian’s adaptive EBRT tools empowers clinicians to adjust therapy in real time, improving outcomes for patients facing both definitive and palliative treatment settings. Moreover, the framework is designed for broad applicability, enabling future use of radiopharmaceutical agents beyond prostate cancer, potentially benefiting patients with kidney cancer, brain tumors, and other solid malignancies.
Policy Significance
This collaboration reflects broader health-policy momentum toward biologically informed radiation oncology, aligning emerging clinical practice with evolving reimbursement, safety, and evidence requirements. As regulatory agencies consider combination-modality approaches, the Telix-Varian framework may support future policy initiatives emphasizing biomarker-guided treatment, adaptive radiation planning, and value-based oncology care models. The integration of advanced imaging with EBRT also aligns with national strategies to improve cancer-care quality, reduce overtreatment, and support equitable access to next-generation technologies—particularly as theranostics become more central to global oncology standards.
The Telix–Varian strategic clinical partnership marks a watershed moment in the evolution of theranostics-enabled radiation oncology, advancing the fusion of molecular imaging and precision EBRT into the clinical mainstream. As the companies move forward with prostate cancer studies and expand co-development into other tumor types, their combined capabilities have the potential to redefine how cancer is imaged, planned, and treated worldwide. This collaboration lays the groundwork for a more personalized, data-driven, and integrated future in oncology—where radiopharmaceuticals and radiation therapy work in unison to deliver superior patient outcomes.
Source: Telix Pharmaceuticals Limited press release
